SCHEMBL14385

SCHEMBL14385

C#Cc1cc(C(=O)N2CCS(=O)(=O)CC2)cc(N2CCN(C(=O)OC(C)(C)C)CC2)c1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
LMNA P02545 2/20 0.41
MAPT P10636 2/20 0.41
ALDH1A1 P00352 1/20 0.41
EGLN2 Q96KS0 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
FAAH O00519 2/20 0.38
CYP2C19 P33261 1/20 0.38
JAK2 O60674 2/20 0.38
JAK1 P23458 2/20 0.38
GPR119 Q8TDV5 5/20 0.38
PDK2 Q15119 1/20 0.37
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
CNR2 P34972 1/20 0.37
NAMPT P43490 1/20 0.37
ABL1 P00519 1/20 0.37
RIN1 Q13671 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14378 0.84 MEN1 (0.44) MEN1KMT2ALMNAMAPTALDH1A1
SCHEMBL24216358 0.74 GPR119 (0.56) MEN1KMT2ALMNAMAPTALDH1A1
SCHEMBL31274032 0.74 CRBN (0.53) MEN1KMT2ALMNAALDH1A1GPR119
SCHEMBL30460245 0.74 GPR119 (0.56) MEN1KMT2ALMNAMAPTALDH1A1
SCHEMBL578665 0.74 MAPT (0.62) MEN1KMT2ALMNAMAPTALDH1A1
SCHEMBL22031505 0.74 KMT2A (0.64) MEN1KMT2AALDH1A1SMN1; SMN2GPR119
SCHEMBL3176506 0.74 MAPT (0.50) MEN1KMT2ALMNAMAPTALDH1A1
SCHEMBL12171691 0.72 MEN1 (0.42) MEN1KMT2AMAPTALDH1A1GPR119
SCHEMBL3392648 0.71 USP2 (0.56) MEN1KMT2ALMNAMAPTALDH1A1
SCHEMBL6346858 0.70 MAPT (0.46) MEN1KMT2ALMNAMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2488525-B1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME MELINTA THERAPEUTICS INC (US) 2018-04-25 EP disclosed
US-20160031893-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME BioVersys AG (CH) 2016-02-04 US disclosed
US-20160031893-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME BioVersys AG (CH) 2016-02-04 US disclosed
US-9193731-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2015-11-24 US disclosed
US-9193731-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2015-11-24 US disclosed
US-20120220566-A1 Antimicrobial Compounds and Methods of Making and Using the Same RIB-X PHARMACEUTICALS, INC. (US) 2012-08-30 US disclosed
US-20120220566-A1 Antimicrobial Compounds and Methods of Making and Using the Same RIB-X PHARMACEUTICALS, INC. (US) 2012-08-30 US disclosed
WO-2011047319-A2 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME RIB-X PHARMACEUTICALS, INC. (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220566-A1 Antimicrobial Compounds and Methods of Making and Using the Same MPO, LPO, CAT MEN1 3118/4885KMT2A 4518/4885LMNA 2222/4885
US-20160031893-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME MPO, LPO, CAT MEN1 3118/4885KMT2A 4518/4885LMNA 2222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.